keyword
MENU ▼
Read by QxMD icon Read
search

iv iron sucrose

keyword
https://www.readbyqxmd.com/read/28063734/safety-of-intravenous-iron-in-hemodialysis-longer-term-comparisons-of-iron-sucrose-versus-sodium-ferric-gluconate-complex
#1
Wolfgang C Winkelmayer, Benjamin A Goldstein, Aya A Mitani, Victoria Y Ding, Medha Airy, Sreedhar Mandayam, Tara I Chang, M Alan Brookhart, Steven Fishbane
BACKGROUND: Controversy exists about any differences in longer-term safety across different intravenous iron formulations routinely used in hemodialysis (HD) patients. We exploited a natural experiment to compare outcomes of patients initiating HD therapy in facilities that predominantly (in ≥90% of their patients) used iron sucrose versus sodium ferric gluconate complex. STUDY DESIGN: Retrospective cohort study of incident HD patients. SETTING & PARTICIPANTS: Using the US Renal Data System, we hard-matched on geographic region and center characteristics HD facilities predominantly using ferric gluconate with similar ones using iron sucrose...
January 4, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28052413/a-randomized-trial-of-iron-isomaltoside-versus-iron-sucrose-in-patients-with-iron-deficiency-anemia
#2
Richard Derman, Eloy Roman, Manuel R Modiano, Maureen M Okam, Lars L Thomsen, Michael Auerbach
Iron deficiency anemia (IDA) is common in many chronic diseases and intravenous (IV) iron offers a rapid and efficient iron correction. This trial compared the efficacy and safety of iron isomaltoside and iron sucrose in patients with IDA who were intolerant of, or unresponsive to, oral iron. The trial was an open-label, comparative, multi-center trial. 511 patients with IDA from different causes were randomized 2:1 to iron isomaltoside or iron sucrose and followed for 5 weeks. The cumulative dose of iron isomaltoside was based on body weight and hemoglobin (Hb), administered as either a 1000 mg infusion over more than 15 minutes or 500 mg injection over 2 minutes...
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28002754/iron-nanomedicines-induce-toll-like-receptor-activation-cytokine-production-and-complement-activation
#3
Johan J F Verhoef, A Marit de Groot, Marc van Moorsel, Jeffrey Ritsema, Nataliia Beztsinna, Coen Maas, Huub Schellekens
Approximately a dozen of intravenous iron nanomedicines gained marketing authorization in the last two decades. These products are generally considered as safe, but have been associated with an increased risk for hypersensitivity-like reactions of which the underlying mechanisms are unknown. We hypothesized that iron nanomedicines can trigger the innate immune system. We hereto investigated the physico-chemical properties of ferric gluconate, iron sucrose, ferric carboxymaltose and iron isomaltoside 1000 and comparatively studied their interaction with Toll-like receptors, the complement system and peripheral blood mononuclear cells...
March 2017: Biomaterials
https://www.readbyqxmd.com/read/27994861/comparison-of-intravenous-low-molecular-weight-iron-dextran-and-intravenous-iron-sucrose-for-the-correction-of-anaemia-in-pre-dialysis-chronic-kidney-disease-patients-a-randomized-single-centre-study-in-nigeria
#4
Bala Waziri, Monica Mabayoje, Babawale Bello
BACKGROUND: Intravenous low molecular weight iron dextran and iron sucrose have been used for correction of iron deficiency for many years and have been shown to improve anaemia in chronic kidney disease (CKD). However, there is a paucity of head to head comparisons of these parenteral iron preparations. Such comparative efficacy data would be of particular interest in resource-limited African countries, where the majority of CKD patients are unable to afford erythropoiesis-stimulating agents...
December 2016: Clinical Kidney Journal
https://www.readbyqxmd.com/read/27971344/cost-outcome-analysis-of-different-intravenous-iron-sucrose-preparations-in-hemodialysis-patients
#5
M Bourdoncle, D Sémély, C Porteils, S Oses, A Pagès, Labadens, M Parmier, B Juillart-Condat, A Del Bello
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27889746/distinct-in-vitro-complement-activation-by-various-intravenous-iron-preparations
#6
Julia Cordelia Hempel, Felix Poppelaars, Mariana Gaya da Costa, Casper F M Franssen, Thomas P G de Vlaam, Mohamed R Daha, Stefan P Berger, Marc A J Seelen, Carlo A J M Gaillard
BACKGROUND: Intravenous (IV) iron preparations are widely used in the treatment of anemia in patients undergoing hemodialysis (HD). All IV iron preparations carry a risk of causing hypersensitivity reactions. However, the pathophysiological mechanism is poorly understood. We hypothesize that a relevant number of these reactions are mediated by complement activation, resulting in a pseudo-anaphylactic clinical picture known as complement activation-related pseudo allergy (CARPA). METHODS: First, the in-vitro complement-activating capacity was determined for 5 commonly used IV iron preparations using functional complement assays for the 3 pathways...
2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/27852236/effects-of-intravenous-iron-on-fibroblast-growth-factor-23-fgf23-in-haemodialysis-patients-a-randomized-controlled-trial
#7
Matthew A Roberts, Louis Huang, Darren Lee, Robert MacGinley, Stefanie M A Troster, Annette B Kent, Sukhvinder S Bansal, Iain C Macdougall, Lawrence P McMahon
BACKGROUND: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used. METHODS: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS)...
November 16, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27577248/-iron-deficiency-fatigue-and-restless-legs-syndrome
#8
Bettina Wurzinger, Peter König
Iron deficiency without anaemia is a widespread health problem that often remains undetected. In this context, neurological and psychopathological problems like fatigue and poor concentration are a major issue, but also in Restless-Legs-Syndrome (RLS) iron deficiency is a key element.The exact pathogenesis is often unknown, however, it is known that iron is involved in several very important metabolic processes in the human body. In particular when it comes to fatigue and RLS, it's assumed that reduced activity of tyrosine hydroxylase - a central iron-dependent element of dopamine synthesis - can lead to deficiencies...
October 2016: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27576956/pediatric-crohn-s-disease-iron-deficiency-anemia-and-intravenous-iron-treatment-a-follow-up-study
#9
Sara Valério de Azevedo, Catarina Maltez, Ana Isabel Lopes
BACKGROUND AND AIMS: Increasing evidence in adults demonstrates efficacy and safety of IV iron in inflammatory Bowel disease (IBD) associated iron deficiency anemia; however, evidence in pediatric patients is yet scarce and no previous study has included a long follow-up. This study aimed to evaluate safety and efficacy of IV iron (primary end point), and the need of re-treatment (secondary end point), in this setting. METHODS: Prospective recruitment (40 months); PCDAI determined before and after treatment; anemia defined according to WHO criteria; IV iron treatment included iron sucrose and ferric carboxymaltose...
January 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27565570/amd-like-retinopathy-associated-with-intravenous-iron
#10
Delu Song, Levi N Kanu, Yafeng Li, Kristen L Kelly, Rupak K Bhuyan, Tomas Aleman, Jessica I W Morgan, Joshua L Dunaief
Iron accumulation in the retina is associated with the development of age-related macular degeneration (AMD). IV iron is a common method to treat iron deficiency anemia in adults, and its retinal manifestations have not hitherto been identified. To assess whether IV iron formulations can be retina-toxic, we generated a mouse model for iron-induced retinal damage. Male C57BL/6J mice were randomized into groups receiving IV iron-sucrose (+Fe) or 30% sucrose (-Fe). Iron levels in neurosensory retina (NSR), retinal pigment epithelium (RPE), and choroid were assessed using immunofluorescence, quantitative PCR, and the Perls' iron stain...
October 2016: Experimental Eye Research
https://www.readbyqxmd.com/read/27565330/dental-pulp-mesenchymal-stem-stromal-cells-labeled-with-iron-sucrose-release-exosomes-and-cells-applied-intra-nasally-migrate-to-intracerebral-glioblastoma
#11
U Altanerova, K Benejova, V Altanerova, S Tyciakova, B Rychly, P Szomolanyi, F Ciampor, M Cihova, V Repiska, K Ondicova, B Mravec, C Altaner
We report on a simple iron oxide (Venofer) labeling procedure of dental pulp mesenchymal stem cells (DP-MSCs) and DP-MSCs transduced with yeast cytosinedeaminase::uracilphosphoribosyltransferase (yCD::UPRT-DP-MSCs). Venofer is a drug approved for intravenous application to treat iron deficiency anemia in patients. Venofer labeling did not affect DP-MSCs or yCD::UPRT-DP-MSCs viability and growth kinetics. Electron microscopy of labeled cells showed internalized Venofer nanoparticles in endosomes. MRI relativity measurement of Venofer labeled DP-MSCs in a phantom arrangement revealed that 100 cells per 0...
2016: Neoplasma
https://www.readbyqxmd.com/read/27542823/is-there-any-role-of-intravenous-iron-for-the-treatment-of-anemia-in-cancer
#12
Cengiz Gemici, Ozlem Yetmen, Gokhan Yaprak, Sevgi Ozden, Huseyin Tepetam, Hazan Ozyurt, Alpaslan Mayadagli
BACKGROUND: Anemia is a major cause of morbidity in patients with cancer resulting in poor physical performance, prognosis and therapy outcome. The aim of this study is to assess the efficacy of intravenous (iv) iron administration for the correction of anemia, for the prevention of exacerbation of anemia, for decreasing blood transfusion rates, and for the survival of cancer patients. METHODS: Patients with different solid tumor diagnosis who received iv iron during their cancer treatment were evaluated retrospectively...
August 20, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27540710/correction-of-iron-deficiency-anemia-with-intravenous-iron-sucrose-in-children-with-inflammatory-bowel-disease
#13
Istvan Danko, Marcy Weidkamp
OBJECTIVES: Iron deficiency anemia (IDA) is common in children with inflammatory bowel disease (IBD) affecting their cognitive development and school performance. Oral iron supplementation has serious limitations including poor adherence and iron malabsorption related to chronic inflammation. Our objective was to evaluate the feasibility of periodic intravenous (IV) iron treatments for correction of IDA in children with IBD. METHODS: This prospective study was conducted in 24 children with IBD treated with infliximab (IFX)...
November 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27462400/ferumoxytol-versus-iron-sucrose-treatment-a-post-hoc-analysis-of-randomized-controlled-trials-in-patients-with-varying-renal-function-and-iron-deficiency-anemia
#14
William E Strauss, Naomi V Dahl, Zhu Li, Gloria Lau, Lee F Allen
BACKGROUND: Iron deficiency anemia is highly prevalent in patients with chronic kidney disease and is often treated with intravenous iron. There are few trials directly comparing the safety and efficacy of different intravenous iron products. METHODS: This post-hoc analysis pooled data from 767 patients enrolled in two randomized, controlled, open-label trials of similar design comparing the treatment of iron deficiency anemia with ferumoxytol and iron sucrose across patients with all stages of renal function...
2016: BMC Hematology
https://www.readbyqxmd.com/read/27455240/assessment-of-dextran-antigenicity-of-intravenous-iron-preparations-with-enzyme-linked-immunosorbent-assay-elisa
#15
Susann Neiser, Taija S Koskenkorva, Katrin Schwarz, Maria Wilhelm, Susanna Burckhardt
Intravenous iron preparations are typically classified as non-dextran-based or dextran/dextran-based complexes. The carbohydrate shell for each of these preparations is unique and is key in determining the various physicochemical properties, the metabolic pathway, and the immunogenicity of the iron-carbohydrate complex. As intravenous dextran can cause severe, antibody-mediated dextran-induced anaphylactic reactions (DIAR), the purpose of this study was to explore the potential of various intravenous iron preparations, non-dextran-based or dextran/dextran-based, to induce these reactions...
July 21, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27358145/reactivity-of-patients-with-maintenance-hemodialysis-to-erythropoietin-in-the-treatment-of-renal-anemia
#16
J P Hu, X Cheng, X F Xu, G J Yu, F Luo, G S Zhang, N Yang, P Shen, X Y Yan
To explore the reactivity of patients with renal anemia (MHD) to erythropoietin (EPO) in maintenance hemodialysis (HD), 31 patients were enrolled in this study. According to the level of serum ferritin (SF), they were divided into two groups; one group received treatment using recombinant human erythropoietin (rHuEPO) and the other group was given iron sucrose. Taking terminal EPO dosage, terminal erythropoietin resistance index (ERI) and rate of change of ERI (ΔERII) as target indexes, the influence of SF level on dosage of EPO was evaluated after usage conditions of relevant substances in a 3-month period...
April 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/27351586/intravenous-iron-therapy-in-non-anemic-iron-deficient-menstruating-adolescent-females-with-fatigue
#17
Ruchika Sharma, Joseph R Stanek, Terah L Koch, Linda Grooms, Sarah H O'Brien
Menstruating women, with or without underlying bleeding disorders, are at increased risk for developing iron deficiency-related fatigue, even in the absence of anemia. Oral iron therapy has limitations which include poor absorption and non-adherence due to gastrointestinal side effects. We performed a prospective clinical trial of post-menarchal adolescent females with iron-deficiency with or without mild anemia and fatigue who received a standardized regimen of intravenous iron sucrose. The baseline mean (SD) hemoglobin was 11...
October 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27269410/comparison-of-intravenous-ferrous-sucrose-and-oral-ferrous-sulphate-in-treatment-of-postpartum-iron-deficiency-anemia
#18
Nabih I El Khouly
OBJECTIVE: The objective of the study was to evaluate the efficacy, safety and tolerability of intravenous ferrous sucrose, compared to oral ferrous sulphate in women with postpartum iron deficiency anemia (IDA). METHODS: In a single center, randomized, controlled study, 352 patients with hemoglobin 9 gm/dl or less and serum ferritin of <15 μg/l two days after delivery were equally randomized to receive intravenous ferrous sucrose (up to three calculated replacement doses) or oral ferrous sulphate (150 mg twice daily for six weeks)...
June 8, 2016: Journal of Maternal-fetal & Neonatal Medicine
https://www.readbyqxmd.com/read/27231440/a-special-meeting-review-edition-ccfa-advances-in-inflammatory-bowel-diseases-2015-highlights-in-ulcerative-colitis-and-crohn-s-disease-a-review-of-selected-presentations-from-the-ccfa-advances-in-inflammatory-bowel-diseases-2015-clinical-and-research-conference
#19
https://www.readbyqxmd.com/read/27199624/response-of-iron-deficiency-anemia-to-intravenous-iron-sucrose-in-pediatric-inflammatory-bowel-disease
#20
Istvan Danko
OBJECTIVES: The objective of this retrospective study was to evaluate the safety and efficacy of intravenous iron sucrose (IS) in iron deficient children with inflammatory bowel disease (IBD) in remission. METHODS: Electronic medical records at a university based pediatric children's hospital were searched for patients in age range 0 to 18 years with diagnosis of IBD and treatment with IS over a 1-year period. Response to IS treatment was assessed by posttreatment changes in ferritin, hemoglobin (Hb), and mean corpuscular volume (MCV)...
March 2016: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
keyword
keyword
30008
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"